Jacobsen Pharma Consultancy A/S has been acquired by PharmaLex GmbH
PharmaLex GmbH, a portfolio company of the funds advised by AUCTUS, has acquired pharma services provider Jacobsen Pharma Consultancy A/S (Jacobsen Pharma). PharmaLex GmbH continues its expansion strategy, opening up the Scandinavian pharmaceutical market. Financial details of this transaction have not been disclosed.
Jacobsen Pharma is a privately owned Danish company offering comprehensive consultancy services to the pharmaceutical and associated industries, from early product development right through to licensing and beyond. Jacobsen Pharma is specialized in providing regulatory affairs, development management and project management support.
In October 2014, funds advised by AUCTUS acquired a controlling stake in YES Pharma Services, a highly specialized service provider in the fields of regulatory affairs, product development and drug safety for pharmaceuticals, medical devices and cosmetics. AUCTUS invested in a growth market at the interface between the pharmaceutical industry and business process outsourcing. After acquiring the company, a rapid growth path was taken with the acquisitions of ActioMed and Wainwright in the second half of 2015, which found its peak in the merger with PharmaLex at the end of 2015.
Oaklins' team in Denmark was mandated to assist the owner in the divestment of Jacobsen Pharma to PE-backed PharmaLex GmbH.
CEO, Jacobsen Pharma Consultancy A/S
Sprechen Sie mit dem Deal-Team
Executive Board MemberKopenhagen, Dänemark
Kalsbeek has been acquired by Normec Group
The shareholders of Kalsbeek BV have sold the company to Normec Group.Mehr erfahren
The Archer Group has been acquired by Bounteous, a portfolio company of Mountaingate Capital
The Archer Group, a leader in digital strategy, experience design, usability research, technology and media, has been acquired by Bounteous, a digital experience agency.Mehr erfahren
Grupo AGP has been acquired by Patria Investments
The private shareholders of Grupo AGP have sold the company to Patria Investments.Mehr erfahren